These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32323879)

  • 1. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
    Lin JP; Zhao YJ; He QL; Hao HK; Tian YT; Zou BB; Jiang LX; Lin W; Zhou YB; Li Z; Xu YC; Zhao G; Xue FQ; Li SL; Fu WH; Li YX; Zhou XJ; Li Y; Zhu ZG; Chen JP; Xu ZK; Cai LH; Li E; Li HL; Xie JW; Huang CM; Li P; Lin JX; Zheng CH
    Br J Surg; 2020 Aug; 107(9):1163-1170. PubMed ID: 32323879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
    Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
    World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
    Okita NT; Kato K; Takahari D; Hirashima Y; Nakajima TE; Matsubara J; Hamaguchi T; Yamada Y; Shimada Y; Taniguchi H; Shirao K
    Gastric Cancer; 2011 Jun; 14(2):161-5. PubMed ID: 21327441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
    Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
    Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach.
    Ma F; Wang B; Xue L; Kang W; Li Y; Li W; Liu H; Ma S; Tian Y
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):2135-2142. PubMed ID: 32306127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.
    Choi NY; Kim BS; Oh ST; Yook JH; Kim BS
    Am Surg; 2021 Apr; 87(4):631-637. PubMed ID: 33142079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study.
    van der Veen A; Seesing MFJ; Wijnhoven BPL; de Steur WO; van Berge Henegouwen MI; Rosman C; van Sandick JW; Mook S; Haj Mohammad N; Ruurda JP; Brosens LAA; van Hillegersberg R;
    Eur J Surg Oncol; 2018 Dec; 44(12):1955-1962. PubMed ID: 30201419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conversion Therapy Using Etoposide and Cisplatin Chemotherapy for Liver Metastases from Advanced Gastric Mixed Adenoneuroendocrine Carcinoma - A Case Report].
    Inaba Y; Fujita M; Ninomiya R; Hashimoto D
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1488-1490. PubMed ID: 29394677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours.
    Pellat A; Walter T; Augustin J; Hautefeuille V; Hentic O; Do Cao C; Lievre A; Coriat R; Hammel P; Dubreuil O; Cohen R; Couvelard A; André T; Svrcek M; Baudin E; Afchain P
    Neuroendocrinology; 2020; 110(5):404-412. PubMed ID: 31430756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients.
    Xie JW; Lu J; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Li P; Huang CM
    BMC Cancer; 2018 Oct; 18(1):1021. PubMed ID: 30348122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma.
    Song IH; Ahn B; Park YS; Kim DH; Hong SM
    Cancer Res Treat; 2024 Sep; ():. PubMed ID: 39327909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
    Abdel-Rahman O; Koski SL
    Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.